



## COMPANY DESCRIPTION

FORMYCON is a leading and independent developer of high-quality biopharmaceutical medicines, especially biosimilars. These are follow-on versions of biopharmaceuticals, for which exclusivity has expired. FORMYCON focuses on treatments in ophthalmology, immunology and on other key chronic diseases and currently has four biosimilars in development. Because of their size and structural complexity, and their production using living cell systems, biosimilars require very significant time, effort and expertise, both in their development and in their subsequent production. Based on its extensive experience in the development of biopharmaceutical medicines, FORMYCON is also working on the development of antibody-based COVID-19 compounds.

PIPELINE	Reference Product Active Ingredient Disease Area	Indications	Partner	Preclinical Phase	Clinical Phase I	Clinical Phase III
<b>FYB</b> <b>201</b>	Lucentis® Ranibizumab Ophthalmology	wAMD, DME, RVO, mCNV, DR*	Bioeq AG	✓	✓	
<b>FYB</b> <b>202</b>	Stelara® Ustekinumab Immunology	Pso, PsA, CD, UC	Aristo Pharma GmbH	✓	→ Start Q3/2020	
<b>FYB</b> <b>203</b>	Eylea® Aflibercept Ophthalmology	wAMD, DME, RVO, DR*, mCNV**	Klinge Biopharma GmbH		→ Start Phase III – Mid-2020	
<b>FYB</b> <b>20X</b>						

\* FDA approved only \*\* EMA approved only

## STRATEGY & GOALS

FORMYCON is specifically concentrating on the “third wave” of biosimilars, namely follow-on products for blockbuster biopharmaceuticals with patent expiries beginning in the year 2020. The company seeks to license out its biosimilar candidates to cooperation partners once certain defined development milestones have been attained to further develop these through to regulatory approval together with the respective partner company. The FORMYCON Group is currently focusing on research and development activities for both its own and out-licensed biosimilar projects, which are the source of its current revenues. After successful approval of the biosimilar candidates, FORMYCON will also participate in the subsequent marketing revenues. Because FORMYCON has focused its efforts on this generation of biosimilars at a timely stage, the company has been able to carve out for itself a unique and leading position in this market space. It's the strategic goal to further strengthen that status and, as a leading independent developer of biosimilars, to assume a key role in this global market. Biosimilars are the drugs of the future. Through their proven efficacy, cost efficiency and high standard of quality, biosimilar medicines are already making a major contribution towards enabling patient access to effective medical treatments. Through its biosimilars, FORMYCON will help not only patients around the world but also contributes to ease the financial strains on the world's healthcare systems.

## FACTS

<b>Founded</b>	2007
<b>Headquarters</b>	Planegg / Munich
<b>Employees</b>	> 100
<b>Management</b>	Dr. Carsten Brockmeyer (CEO) Dr. Nicolas Combé (CFO) Dr. Stefan Glombitza (COO)
<b>Supervisory Board</b>	Dr. Olaf Stiller (Chairman) Hermann Vogt (Deputy Chairman) Peter Wendeln (Member Supervisory Board)

## KEY FINANCIALS (in € million)

	2016	2017	2018	2019
<b>Revenue</b>	19.5	29.4	43.0	33.2
<b>EBITDA</b>	-4.1	-1.5	7.1	-1.4
<b>Net Income</b>	-4.1	-1.6	7.1	-2.3
<b>Equity Ratio (in %)</b>	82.9	82.9	83.9	90.0

## HIGHLIGHTS 2019/2020

<b>MAY 2020</b>	Formycon publishes Annual Financial Statements for the 2019 Financial Year
<b>MAY 2020</b>	Formycon announces Update on Biosimilar Programs
<b>MAY 2020</b>	Formycon is postponing the General Assembly into the fourth Quarter of 2020 to maintain the Possibility of an Event in Person
<b>APR 2020</b>	Formycon starts Antibody-Based Drug Development for COVID-19
<b>FEB 2020</b>	Formycon informs about the current Status of the BLA Review Process of the Lucentis® Biosimilar Candidate FYB201
<b>NOV 2019</b>	Bioeq IP exclusively licenses US Marketing Rights for FYB201 to Coherus BioSciences, Inc.
<b>OCT 2019</b>	Formycon announces Start of Phase I Clinical Trial with Ustekinumab Biosimilar Candidate FYB202

## FINANCIAL CALENDAR

Publication of Annual Report 2019	May 18, 2020
Statement Q1 / 2020	June 2020
Publication of Half-Year Report 2020	September 2020
Statement Nine-Month Figures 2020	November 2020
Annual General Meeting 2020	December 10, 2020

## MARKET DATA

ISIN	DE000A1EWVY8
Market Segment	Frankfurt, Stock Exchange „Scale“
Market Capitalization	~ € 250 million
Outstanding Shares	10,000,000
Shareholder Structure	15 % Institutional Investors 35 % Family Offices 15 % Founders and Management 35 % Free Float

**CONTACT:** Sabrina Müller Corporate Communications & Investor Relations Phone + 49 89 86 46 67 149 E-Mail: [sabrina.mueller@formycon.com](mailto:sabrina.mueller@formycon.com)

This document may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, FORMYCON AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. FORMYCON AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of FORMYCON AG. No public offering of securities of FORMYCON AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.